|
1
|
Travis WD, Brambilla E, Burke AP, Marx A
and Nicholson AG: Tumours of the lung. Who Classification Of
Tumours Of Lung, Pleura, Thymus And Heart (4th). IARC Press. (Lyon,
France). 9–151. 2015.
|
|
2
|
Kwak EL, Bang YJ, Camidge DR, Shaw AT,
Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, et al:
Anaplastic lymphoma kinase inhibition in non-small-cell lung
cancer. N Engl J Med. 363:1693–1703. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Patel JN, Ersek JL and Kim ES: Lung cancer
biomarkers, targeted therapies and clinical assays. Transl Lung
Cancer Res. 4:503–514. 2015.PubMed/NCBI
|
|
4
|
Lindeman NI, Cagle PT, Beasley MB, Chitale
DA, Dacic S, Giaccone G, Jenkins RB, Kwiatkowski DJ, Saldivar JS,
Squire J, et al: Molecular testing guideline for selection of lung
cancer patients for EGFR and ALK tyrosine kinase inhibitors:
Guideline from the College of American pathologists, international
association for the study of lung cancer, and association for
molecular pathology. J Thorac Oncol. 8:823–859. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Soda M, Choi YL, Enomoto M, Takada S,
Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K,
Hatanaka H, et al: Identification of the transforming EML4-ALK
fusion gene in non-small-cell lung cancer. Nature. 448:561–566.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Vidal J, Clavé S, de Muga S, González I,
Pijuan L, Gimeno J, Remón J, Reguart N, Viñolas N, Gironés R, et
al: Assessment of ALK status by FISH on 1,000 Spanish non-small
cell lung cancer patients. J Thorac Oncol. 9:1816–1820. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Alì G, Proietti A, Pelliccioni S, Niccoli
C, Lupi C, Sensi E, Giannini R, Borrelli N, Menghi M, Chella A, et
al: ALK rearrangement in a large series of consecutive non-small
cell lung cancers: Comparison between a new immunohistochemical
approach and fluorescence in situ hybridization for the screening
of patients eligible for crizotinib treatment. Arch Pathol Lab Med.
138:1449–1458. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cabillic F, Gros A, Dugay F, Begueret H,
Mesturoux L, Chiforeanu DC, Dufrenot L, Jauffret V, Dachary D,
Corre R, et al: Parallel FISH and immunohistochemical studies of
ALK status in 3,244 non-small-cell lung cancers reveal major
discordances. J Thorac Oncol. 9:295–306. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhao F, Xu M, Lei H, Zhou Z, Wang L, Li P,
Zhao J and Hu P: Clinicopathological characteristics of patients
with non-small-cell lung cancer who harbor EML4-ALK fusion gene: A
meta-analysis. PLoS One. 10:e01173332015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ou SH, Klempner SJ, Greenbowe JR, Azada M,
Schrock AB, Ali SM, Ross JS, Stephens PJ and Miller VA:
Identification of a novel HIP1-ALK fusion variant in non-small-cell
lung cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations
in two ALK-rearranged NSCLC patients with resistance to Alectinib.
J Thorac Oncol. 9:1821–1825. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Iyevleva AG, Raskin GA, Tiurin VI,
Sokolenko AP, Mitiushkina NV, Aleksakhina SN, Garifullina AR,
Strelkova TN, Merkulov VO, Ivantsov AO, et al: Novel ALK fusion
partners in lung cancer. Cancer Lett. 362:116–121. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Conde E, Suárez-Gauthier A, Benito A,
Garrido P, García-Campelo R, Biscuola M, Paz-Ares L, Hardisson D,
de Castro J, Camacho MC, et al: Accurate identification of ALK
positive lung carcinoma patients: Novel FDA-cleared automated
fluorescence in situ hybridization scanning system and
ultrasensitive immunohistochemistry. PLoS One. 9:e1072002014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang Q, Yang X, He Y, Ma Q, Lin L, Fu P
and Xiao H: Droplet digital PCR for absolute quantification of
EML4-ALK gene rearrangement in lung adenocarcinoma. J Mol Diagn.
17:515–520. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mancikova V, Cruz R, Inglada-Pérez L,
Fernández-Rozadilla C, Landa I, Cameselle-Teijeiro J, Celeiro C,
Pastor S, Velázquez A, Marcos R, et al: Thyroid cancer GWAS
identifies 10q26.12 and 6q14.1 as novel susceptibility loci and
reveals genetic heterogeneity among populations. Int J Cancer.
137:1870–1878. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bozzetti C, Nizzoli R, Tiseo M, Squadrilli
A, Lagrasta C, Buti S, Gasparro D, Zanoni D, Majori M, De Filippo
M, et al: ALK and ROS1 rearrangements tested by fluorescence in
situ hybridization in cytological smears from advanced non-small
cell lung cancer patients. Diagn Cytopathol. 43:941–946. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Proietti A, Alì G, Pelliccioni S, Lupi C,
Sensi E, Boldrini L, Servadio A, Chella A, Ribechini A, Cappuzzo F,
et al: Anaplastic lymphoma kinase gene rearrangements in
cytological samples of non-small cell lung cancer: Comparison with
histological assessment. Cancer Cytopathol. 122:445–1453. 2014.
View Article : Google Scholar : PubMed/NCBI
|
